Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umbralisib + Brentuximab Vedotin in Hodgkin Lymphoma
NCT02164006Phase 1Completed
- Sponsor
- TG Therapeutics, Inc.
- Start
- Jun 2014
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of umbralisib in Hodgkin lymphoma (HL), sponsored by TG Therapeutics, Inc. Primary endpoint: Maximum Tolerated Dose at 21 days. Started Jun 2014; status: completed.
02
Drugs
umbralisib
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT02164006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02164006.